UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
See also List of investigational sexual dysfunction drugs ABT-670 ABT-724 Bremelanotide Cabergoline Flibanserin Testosterone (patch) Melanotan II Pramipexole PF-219,061 S-17092 Tibolone
References


